Compass Therapeutics develops antibody therapeutics that target the immune synapse for treatment of cancer. The immune synapse is the term for the molecular interactions which are part of an immune response which takes place in the gap between T cells and antigen presenting cells. Proper regulation ensures a balance where the host defends against pathogens and tumors and also does not develop autoimmunity. Compass Therapeutics is developing antibodies that engage T cells, NK cells and macrophages to promote tumor-specific activation or reverse immune suppression.
The company’s lead candidate as of 2020 was CTX-471, a fully human agonistic antibody of CD137 in clinical Phase 1 studies in patients with advanced solid tumors. Compass’s CTX-8371 drug in development is a novel PD-1/PD-L1 bispecific antibody.
Thomas Schuetz, M.D., Ph.D